Obesity News | Updates

Lilly's tirzepatide reduced weight loss up to 22.5% in obese or overweight individuals.

In the Phase 3 trial SURMOUNT-1, Lilly's tirzepatide reduced the weight at week 72 compared to placebo, and participants lost weight up to 24 kg. The trial enrolled 2,539 participants and was intended to evaluate the efficacy of tirzepatide in adults with obesity or overweight and with one co-morbidity without diabetes.

The primary endpoints of the clinical trial were percentage change from baseline in body weight and participants achieving ≥5% bodyweight reduction.


The company announced that its safety profile is in-line with other incretin-based therapies approved for obesity.

0 comments